Logo image of RGLS

REGULUS THERAPEUTICS INC (RGLS) Stock Fundamental Analysis

NASDAQ:RGLS - Nasdaq - US75915K3095 - Common Stock - Currency: USD

2.33  +0.01 (+0.43%)

Fundamental Rating

3

Overall RGLS gets a fundamental rating of 3 out of 10. We evaluated RGLS against 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RGLS as it has an excellent financial health rating, but there are worries on the profitability. RGLS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RGLS had negative earnings in the past year.
RGLS had a negative operating cash flow in the past year.
In the past 5 years RGLS always reported negative net income.
In the past 5 years RGLS always reported negative operating cash flow.
RGLS Yearly Net Income VS EBIT VS OCF VS FCFRGLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -55.07%, RGLS is in line with its industry, outperforming 43.49% of the companies in the same industry.
RGLS has a Return On Equity (-60.67%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -55.07%
ROE -60.67%
ROIC N/A
ROA(3y)-71.13%
ROA(5y)-59.17%
ROE(3y)-95.84%
ROE(5y)-79.71%
ROIC(3y)N/A
ROIC(5y)N/A
RGLS Yearly ROA, ROE, ROICRGLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

RGLS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RGLS Yearly Profit, Operating, Gross MarginsRGLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, RGLS has more shares outstanding
RGLS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RGLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RGLS Yearly Shares OutstandingRGLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RGLS Yearly Total Debt VS Total AssetsRGLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of 1.66, we must say that RGLS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of RGLS (1.66) is better than 71.83% of its industry peers.
RGLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.66
ROIC/WACCN/A
WACCN/A
RGLS Yearly LT Debt VS Equity VS FCFRGLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 10.98 indicates that RGLS has no problem at all paying its short term obligations.
RGLS has a better Current ratio (10.98) than 82.92% of its industry peers.
A Quick Ratio of 10.98 indicates that RGLS has no problem at all paying its short term obligations.
RGLS's Quick ratio of 10.98 is amongst the best of the industry. RGLS outperforms 82.92% of its industry peers.
Industry RankSector Rank
Current Ratio 10.98
Quick Ratio 10.98
RGLS Yearly Current Assets VS Current LiabilitesRGLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

RGLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.28%, which is quite impressive.
EPS 1Y (TTM)45.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RGLS will show a very strong growth in Earnings Per Share. The EPS will grow by 45.99% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-49.6%
EPS Next 2Y-27.47%
EPS Next 3Y-9.83%
EPS Next 5Y45.99%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RGLS Yearly Revenue VS EstimatesRGLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
RGLS Yearly EPS VS EstimatesRGLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RGLS. In the last year negative earnings were reported.
Also next year RGLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGLS Price Earnings VS Forward Price EarningsRGLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGLS Per share dataRGLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A cheap valuation may be justified as RGLS's earnings are expected to decrease with -9.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.47%
EPS Next 3Y-9.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RGLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REGULUS THERAPEUTICS INC

NASDAQ:RGLS (4/23/2025, 10:54:00 AM)

2.33

+0.01 (+0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2025-03-13/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners83.41%
Inst Owner Change-0.02%
Ins Owners2.21%
Ins Owner Change1.36%
Market Cap154.34M
Analysts85
Price Target12.04 (416.74%)
Short Float %3.5%
Short Ratio4.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.24%
Min EPS beat(2)-21.11%
Max EPS beat(2)6.63%
EPS beat(4)1
Avg EPS beat(4)-13.97%
Min EPS beat(4)-27.78%
Max EPS beat(4)6.63%
EPS beat(8)5
Avg EPS beat(8)-4.6%
EPS beat(12)7
Avg EPS beat(12)-0.56%
EPS beat(16)9
Avg EPS beat(16)-1.33%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)14.19%
PT rev (3m)14.19%
EPS NQ rev (1m)-4.26%
EPS NQ rev (3m)-4.26%
EPS NY rev (1m)-3.04%
EPS NY rev (3m)-3.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.02
P/tB 2.02
EV/EBITDA N/A
EPS(TTM)-0.87
EYN/A
EPS(NY)-1.3
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0
BVpS1.15
TBVpS1.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.07%
ROE -60.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.13%
ROA(5y)-59.17%
ROE(3y)-95.84%
ROE(5y)-79.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 97.98%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.98
Quick Ratio 10.98
Altman-Z 1.66
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)221.31%
Cap/Depr(5y)143.72%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y-49.6%
EPS Next 2Y-27.47%
EPS Next 3Y-9.83%
EPS Next 5Y45.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-60.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.02%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-53.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.68%
OCF growth 3YN/A
OCF growth 5YN/A